Management of Severe Toxicity and Shock

Initial Management

• Check and correct hypoglycemia and hypocalcemia immediately, as recommended by the American College of Critical Care Medicine 1
• If septic shock is suspected, ensure broad-spectrum antibiotics have been administered within the first hour, as recommended by the American College of Critical Care Medicine 1
• Consider sodium bicarbonate administration (1-2 mEq/kg IV bolus) if severe metabolic acidosis is present, especially with pH < 7.2, as suggested by the American Heart Association 2

Pharmacological Interventions

• Add dobutamine (2-20 μg/kg/min) if evidence suggests myocardial depression, as recommended by the European Society of Cardiology 3, 4
• Consider milrinone (0.375-0.75 μg/kg/min) especially if patient is on beta-blockers, as recommended by the European Society of Cardiology 3, 4
• Levosimendan (0.1 μg/kg/min) may be considered if available, as suggested by the European Society of Cardiology 3, 4
• For beta-blocker toxicity: Consider glucagon (5-10 mg IV bolus followed by 1-5 mg/hour infusion), as recommended by the American Heart Association 2
• For calcium channel blocker toxicity: Consider calcium chloride (20 mg/kg of 10% solution), as recommended by the American Heart Association 2
• Consider high-dose insulin therapy in either scenario, as suggested by the American Heart Association 2
• Consider nitroglycerin and benzodiazepines, as recommended by the American Heart Association 2
• Avoid beta-blockers, as recommended by the American Heart Association 2

Infection Management

• If infection is the suspected cause, ensure aggressive source control with drainage or debridement as needed, as recommended by the American College of Critical Care Medicine 1
• Consider clindamycin if toxic shock syndrome is suspected, as recommended by the American College of Critical Care Medicine 1
• Administer empirical antibiotics within the first hour of identifying severe sepsis, as recommended by the American College of Critical Care Medicine 1

Vasopressor Management

• The American College of Critical Care Medicine recommends norepinephrine as the first-choice vasopressor for fluid-refractory shock, starting at 0.05-0.1 μg/kg/min and titrating by 0.05-0.1 μg/kg/min every 5-15 minutes to achieve a target mean arterial pressure (MAP) ≥65 mmHg 5, 6, 1, 7, 8, 9, 10, 11
• Vasopressin may be added to raise MAP or decrease norepinephrine requirements, at a dose of up to 0.03 U/min (fixed dose), but is not recommended as a single initial vasopressor 5, 8
• Epinephrine may be considered when an additional agent is needed to maintain adequate blood pressure, particularly if there's evidence of myocardial depression 5, 8
• Dopamine may be used in highly selected patients with low risk of tachyarrhythmias and absolute or relative bradycardia, but evidence suggests worse outcomes with dopamine compared to norepinephrine 12
• The following vasopressor dosing guidelines are recommended:

11

Fluid Management

• Administer isotonic crystalloid boluses of 20 mL/kg to restore intravascular volume, as recommended by the American College of Critical Care Medicine and the American Heart Association, with continuous evaluation after each bolus to detect signs of improvement, volume overload, and the need for vasoactive support 12, 13, 1
• Continue fluid boluses (up to 60 mL/kg in the first hour) while monitoring for signs of fluid overload, as guided by the American College of Critical Care Medicine 12
• Avoid routine administration of fluid boluses in patients with severe febrile illness who do not present with shock, as suggested by the American Heart Association 13
• Avoid using hydroxyethyl starches for fluid resuscitation in septic shock, as recommended by the Society of Critical Care Medicine (Grade 1B) 6
• Consider colloids in specific cases of refractory shock with hypoalbuminemia or significant capillary leak, while avoiding volume overload to prevent compromising pulmonary function and causing pulmonary edema 14

Monitoring and Support

• Monitor serum electrolytes, urea nitrogen, and creatinine daily, as suggested by the European Society of Cardiology 15
• Establish arterial line monitoring when using vasopressors, as recommended by the Society of Critical Care Medicine 6
• Monitor parameters such as blood pressure, heart rate, urine output, skin perfusion, mental status, lactate clearance, and renal and liver function tests, with a goal of maintaining SpO₂ ≥ 95%, mean arterial pressure (MAP) ≥ 65 mmHg, and urine output ≥ 0.5 ml/kg/h, as recommended by the Critical Care society and the Intensive Care Medicine guidelines, with a high strength of evidence 16, 8
• Wean vasopressors as soon as hemodynamic stabilization is achieved, according to the Society of Critical Care Medicine 8
• Consider intra-aortic balloon pump (IABP) for refractory cases despite pharmacological therapy, as suggested by the European Society of Cardiology 4
• Evaluate for left ventricular assist device (LVAD) for potentially reversible causes, as recommended by the European Society of Cardiology 4
• Consider ECMO support in refractory septic shock and respiratory failure 1
• Consider early intubation in patients with increased respiratory effort or hypoxemia 1
• Consider hydrocortisone (up to 300 mg/day) if escalating vasopressor doses are required, particularly in patients with suspicion of relative adrenal insufficiency, as recommended by the Society of Critical Care Medicine, with a moderate strength of evidence 17, 18

Special Considerations

• Low-dose arginine vasopressin (≤0.04 units/kg/min) has short-term hemodynamic benefits in children with vasodilatory shock, according to the Society of Critical Care Medicine 12
• Monitoring for adverse effects, including cardiac and peripheral ischemia, arrhythmias, hypertension, and bowel ischemia, is recommended by the American Association for the Study of Liver Diseases 19
• Monitor patients closely for signs of myocardial dysfunction, myocardial ischemia, and other complications, especially in those with cardiac conditions or aortic stenosis, as recommended by the Critical Care society and the European Heart Society 20, 7